Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Weekly Tocilizumab Provides Durable Benefits For Giant Cell Arteritis Patients

Publish date:: November 13, 2019

Key clinical point: Weekly tocilizumab provides durable benefits for GCA patients.

Major finding: 47% of weekly tocilizumab recipients maintained clinical remission throughout the extension period.

Study details: A 2-year extension involving 215 participants from the phase 3 GiACTA trial.

Disclosures: GiACTA was funded by Roche. Dr. Stone reported research grants from Roche/Genentech, and consulting fees from Chugal, Roche/Genentech, and Xencor.

Citation:

Stone J et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 808.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Rheumatology

Osteoporosis prevalence in PsA similar to general population,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,